Kumar Srinivasan
Direktor/Vorstandsmitglied bei TRANSCENTA HOLDING LIMITED
Vermögen: 6 943 $ am 30.04.2024
Profil
Kumar Srinivasan is currently the President & Chief Executive Officer at Wugen, Inc. He is also a Director at Pulmotect, Inc. and an Independent Non-Executive Director at Transcenta Holding Ltd.
Previously, he worked as the Chief Business Officer & Executive Vice President at Turning Point Therapeutics, Inc. Dr. Srinivasan holds a doctorate degree from Case Western Reserve University, undergraduate and graduate degrees from the University of Madras, and an MBA from The University of Chicago Booth School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 06.04.2023 | 30 000 ( 0,01% ) | 6 943 $ | 30.04.2024 |
Aktive Positionen von Kumar Srinivasan
| Unternehmen | Position | Beginn |
|---|---|---|
| TRANSCENTA HOLDING LIMITED | Direktor/Vorstandsmitglied | 19.12.2022 |
Pulmotect, Inc.
 Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Direktor/Vorstandsmitglied | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Vorstandsvorsitzender | 13.03.2023 |
Ehemalige bekannte Positionen von Kumar Srinivasan
| Unternehmen | Position | Ende |
|---|---|---|
| TURG POIN | Corporate Officer/Principal | - |
Ausbildung von Kumar Srinivasan
| Case Western Reserve University | Doctorate Degree |
| University of Madras | Graduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TRANSCENTA HOLDING LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
